CLINDAMYCIN INJECTION IN 5% DEXTROSE SOLUTION

Pajjiż: Kanada

Lingwa: Ingliż

Sors: Health Canada

Ingredjent attiv:

CLINDAMYCIN (CLINDAMYCIN PHOSPHATE)

Disponibbli minn:

BAXTER CORPORATION

Kodiċi ATC:

J01FF01

INN (Isem Internazzjonali):

CLINDAMYCIN

Dożaġġ:

600MG

Għamla farmaċewtika:

SOLUTION

Kompożizzjoni:

CLINDAMYCIN (CLINDAMYCIN PHOSPHATE) 600MG

Rotta amministrattiva:

INTRAVENOUS

Unitajiet fil-pakkett:

15G/50G

Tip ta 'preskrizzjoni:

Prescription

Żona terapewtika:

LINCOMYCINS

Sommarju tal-prodott:

Active ingredient group (AIG) number: 0105830009; AHFS:

L-istatus ta 'awtorizzazzjoni:

APPROVED

Data ta 'l-awtorizzazzjoni:

2019-02-04

Karatteristiċi tal-prodott

_Clindamycin Injection in 5% Dextrose_
_Page 1 of 33 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
CLINDAMYCIN INJECTION IN 5% DEXTROSE
Ready-to-use bags, clindamycin 6 mg / mL (300 mg / 50 mL), 12 mg / mL
(600 mg /
50 mL) and
18 mg / mL (900 mg / 50 mL) (as clindamycin phosphate)
STERILE SOLUTION
ANTIBIOTIC
Baxter Corporation
7125 Mississauga Road
Mississauga, Ontario
L5N 0C2
Date of Revision:
February 1, 2019
Submission Control No: 212923
Baxter and GALAXY are trademarks of Baxter International Inc.
_Clindamycin Injection in 5% Dextrose_
_Page 2 of 33 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................... 3
SUMMARY PRODUCT INFORMATION
..........................................................................
3
INDICATIONS AND CLINICAL USE
................................................................................
3
CONTRAINDICATIONS
.....................................................................................................
5
WARNINGS AND PRECAUTIONS
....................................................................................
5
ADVERSE REACTIONS
......................................................................................................
8
DRUG INTERACTIONS
....................................................................................................
10
DOSAGE AND ADMINISTRATION
................................................................................
11
OVERDOSAGE
...................................................................................................................
13
ACTION AND CLINICAL PHARMACOLOGY
.............................................................. 13
STORAGE AND STABILITY
............................................................................................
15
SPECIAL HANDLING INSTRUCTIONS
.........................................................................
15
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................. 16